Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2 Study of Futibatinib in Patients With FGFR Aberrations
2019-004084-49Phase 2Completed
- Sponsor
- Taiho Oncology
- Start
- Apr 2020
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Allosteric Modulators → Classical Binding Small Molecules → Small Molecules, Irreversible Covalent Inhibitors → Covalent Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label trial of futibatinib in FGFR-rearranged solid tumor, gastric cancer (GC) and esophagogastric junction cancer (2 cohorts), sponsored by Taiho Oncology. Primary endpoint: Objective response rate by independent review (Cohorts A and B). Started Apr 2020; status: completed.
02
Drugs
futibatinib
03
Conditions
FGFR-rearranged solid tumorgastric cancer (GC)esophagogastric junction cancer
Beyond the preview
Go deeper on 2019-004084-49.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2019-004084-49.